The anti-fibrotic capacity of EVs is achieved by the suppression of TGF-β1–SMAD2/3 signalling, therefore preventing excessive extracellular matrix deposition in the ovarian cortex, a phenomenon observed in advanced PCOS disease [196]. Here, TGFB1 is linked to polycystic ovary syndrome.